Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia

Shinichiro Nakajima, Hiroyoshi Takeuchi, Eric Plitman, Gagan Fervaha, Philip Gerretsen, Fernando Caravaggio, Jun Ku Chung, Yusuke Iwata, Gary Remington, Ariel Graff-Guerrero

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Background: Recent developments in neuroimaging have advanced the understanding of biological mechanisms underlying schizophrenia. However, neuroimaging correlates of treatment-resistant schizophrenia (TRS) and superior effects of clozapine on TRS remain unclear. Methods: Systematic search was performed to identify neuroimaging characteristics unique to TRS and ultra-resistant schizophrenia (i.e. clozapine-resistant [URS]), and clozapine's efficacy in TRS using Embase, Medline, and PsychInfo. Search terms included (schizophreni*) and (resistan* OR refractory OR clozapine) and (ASL OR CT OR DTI OR FMRI OR MRI OR MRS OR NIRS OR PET OR SPECT). Results: 25 neuroimaging studies have investigated TRS and effects of clozapine. Only 5 studies have compared TRS and non-TRS, collectively providing no replicated neuroimaging finding specific to TRS. Studies comparing TRS and healthy controls suggest that hypometabolism in the prefrontal cortex, hypermetabolism in the basal ganglia, and structural anomalies in the corpus callosum contribute to TRS. Clozapine may increase prefrontal hypoactivation in TRS although this was not related to clinical improvement; in contrast, evidence has suggested a link between clozapine efficacy and decreased metabolism in the basal ganglia and thalamus. Conclusion: Existing literature does not elucidate neuroimaging correlates specific to TRS or URS, which, if present, might also shed light on clozapine's efficacy in TRS. This said, leads from other lines of investigation, including the glutamatergic system can prove useful in guiding future neuroimaging studies focused on, in particular, the frontocortical-basal ganglia-thalamic circuits. Critical to the success of this work will be precise subtyping of study subjects based on treatment response/nonresponse and the use of multimodal neuroimaging.

Original languageEnglish
Pages (from-to)164-175
Number of pages12
JournalSchizophrenia Research
Volume164
Issue number1-3
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Neuroimaging
Schizophrenia
Clozapine
Basal Ganglia
Corpus Callosum
Pets
Prefrontal Cortex
Single-Photon Emission-Computed Tomography
Thalamus

Keywords

  • Clozapine
  • Glutamate
  • Neuroimaging
  • Schizophrenia
  • Treatment-resistance

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Neuroimaging findings in treatment-resistant schizophrenia : A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. / Nakajima, Shinichiro; Takeuchi, Hiroyoshi; Plitman, Eric; Fervaha, Gagan; Gerretsen, Philip; Caravaggio, Fernando; Chung, Jun Ku; Iwata, Yusuke; Remington, Gary; Graff-Guerrero, Ariel.

In: Schizophrenia Research, Vol. 164, No. 1-3, 01.05.2015, p. 164-175.

Research output: Contribution to journalReview article

Nakajima, Shinichiro ; Takeuchi, Hiroyoshi ; Plitman, Eric ; Fervaha, Gagan ; Gerretsen, Philip ; Caravaggio, Fernando ; Chung, Jun Ku ; Iwata, Yusuke ; Remington, Gary ; Graff-Guerrero, Ariel. / Neuroimaging findings in treatment-resistant schizophrenia : A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. In: Schizophrenia Research. 2015 ; Vol. 164, No. 1-3. pp. 164-175.
@article{b0271594ccf84dc6b1d76a0a872575d1,
title = "Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia",
abstract = "Background: Recent developments in neuroimaging have advanced the understanding of biological mechanisms underlying schizophrenia. However, neuroimaging correlates of treatment-resistant schizophrenia (TRS) and superior effects of clozapine on TRS remain unclear. Methods: Systematic search was performed to identify neuroimaging characteristics unique to TRS and ultra-resistant schizophrenia (i.e. clozapine-resistant [URS]), and clozapine's efficacy in TRS using Embase, Medline, and PsychInfo. Search terms included (schizophreni*) and (resistan* OR refractory OR clozapine) and (ASL OR CT OR DTI OR FMRI OR MRI OR MRS OR NIRS OR PET OR SPECT). Results: 25 neuroimaging studies have investigated TRS and effects of clozapine. Only 5 studies have compared TRS and non-TRS, collectively providing no replicated neuroimaging finding specific to TRS. Studies comparing TRS and healthy controls suggest that hypometabolism in the prefrontal cortex, hypermetabolism in the basal ganglia, and structural anomalies in the corpus callosum contribute to TRS. Clozapine may increase prefrontal hypoactivation in TRS although this was not related to clinical improvement; in contrast, evidence has suggested a link between clozapine efficacy and decreased metabolism in the basal ganglia and thalamus. Conclusion: Existing literature does not elucidate neuroimaging correlates specific to TRS or URS, which, if present, might also shed light on clozapine's efficacy in TRS. This said, leads from other lines of investigation, including the glutamatergic system can prove useful in guiding future neuroimaging studies focused on, in particular, the frontocortical-basal ganglia-thalamic circuits. Critical to the success of this work will be precise subtyping of study subjects based on treatment response/nonresponse and the use of multimodal neuroimaging.",
keywords = "Clozapine, Glutamate, Neuroimaging, Schizophrenia, Treatment-resistance",
author = "Shinichiro Nakajima and Hiroyoshi Takeuchi and Eric Plitman and Gagan Fervaha and Philip Gerretsen and Fernando Caravaggio and Chung, {Jun Ku} and Yusuke Iwata and Gary Remington and Ariel Graff-Guerrero",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.schres.2015.01.043",
language = "English",
volume = "164",
pages = "164--175",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Neuroimaging findings in treatment-resistant schizophrenia

T2 - A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia

AU - Nakajima, Shinichiro

AU - Takeuchi, Hiroyoshi

AU - Plitman, Eric

AU - Fervaha, Gagan

AU - Gerretsen, Philip

AU - Caravaggio, Fernando

AU - Chung, Jun Ku

AU - Iwata, Yusuke

AU - Remington, Gary

AU - Graff-Guerrero, Ariel

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: Recent developments in neuroimaging have advanced the understanding of biological mechanisms underlying schizophrenia. However, neuroimaging correlates of treatment-resistant schizophrenia (TRS) and superior effects of clozapine on TRS remain unclear. Methods: Systematic search was performed to identify neuroimaging characteristics unique to TRS and ultra-resistant schizophrenia (i.e. clozapine-resistant [URS]), and clozapine's efficacy in TRS using Embase, Medline, and PsychInfo. Search terms included (schizophreni*) and (resistan* OR refractory OR clozapine) and (ASL OR CT OR DTI OR FMRI OR MRI OR MRS OR NIRS OR PET OR SPECT). Results: 25 neuroimaging studies have investigated TRS and effects of clozapine. Only 5 studies have compared TRS and non-TRS, collectively providing no replicated neuroimaging finding specific to TRS. Studies comparing TRS and healthy controls suggest that hypometabolism in the prefrontal cortex, hypermetabolism in the basal ganglia, and structural anomalies in the corpus callosum contribute to TRS. Clozapine may increase prefrontal hypoactivation in TRS although this was not related to clinical improvement; in contrast, evidence has suggested a link between clozapine efficacy and decreased metabolism in the basal ganglia and thalamus. Conclusion: Existing literature does not elucidate neuroimaging correlates specific to TRS or URS, which, if present, might also shed light on clozapine's efficacy in TRS. This said, leads from other lines of investigation, including the glutamatergic system can prove useful in guiding future neuroimaging studies focused on, in particular, the frontocortical-basal ganglia-thalamic circuits. Critical to the success of this work will be precise subtyping of study subjects based on treatment response/nonresponse and the use of multimodal neuroimaging.

AB - Background: Recent developments in neuroimaging have advanced the understanding of biological mechanisms underlying schizophrenia. However, neuroimaging correlates of treatment-resistant schizophrenia (TRS) and superior effects of clozapine on TRS remain unclear. Methods: Systematic search was performed to identify neuroimaging characteristics unique to TRS and ultra-resistant schizophrenia (i.e. clozapine-resistant [URS]), and clozapine's efficacy in TRS using Embase, Medline, and PsychInfo. Search terms included (schizophreni*) and (resistan* OR refractory OR clozapine) and (ASL OR CT OR DTI OR FMRI OR MRI OR MRS OR NIRS OR PET OR SPECT). Results: 25 neuroimaging studies have investigated TRS and effects of clozapine. Only 5 studies have compared TRS and non-TRS, collectively providing no replicated neuroimaging finding specific to TRS. Studies comparing TRS and healthy controls suggest that hypometabolism in the prefrontal cortex, hypermetabolism in the basal ganglia, and structural anomalies in the corpus callosum contribute to TRS. Clozapine may increase prefrontal hypoactivation in TRS although this was not related to clinical improvement; in contrast, evidence has suggested a link between clozapine efficacy and decreased metabolism in the basal ganglia and thalamus. Conclusion: Existing literature does not elucidate neuroimaging correlates specific to TRS or URS, which, if present, might also shed light on clozapine's efficacy in TRS. This said, leads from other lines of investigation, including the glutamatergic system can prove useful in guiding future neuroimaging studies focused on, in particular, the frontocortical-basal ganglia-thalamic circuits. Critical to the success of this work will be precise subtyping of study subjects based on treatment response/nonresponse and the use of multimodal neuroimaging.

KW - Clozapine

KW - Glutamate

KW - Neuroimaging

KW - Schizophrenia

KW - Treatment-resistance

UR - http://www.scopus.com/inward/record.url?scp=84929281198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929281198&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2015.01.043

DO - 10.1016/j.schres.2015.01.043

M3 - Review article

C2 - 25684554

AN - SCOPUS:84929281198

VL - 164

SP - 164

EP - 175

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -